Audit: QRS - Microdosing Ketamine for Health & Longevity
Audit conducted on 30/09/2026 05:16 using AI4L + evidence-mcp / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 86 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol, time-to-effect, benefits, risks, gates, monitoring and lede all trace to ER passages (e.g., Therapeutic Protocol l.371-376, Practical Considerations l.407, Monitoring table l.428-436) |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Theoretical additive NMDA … blockade”, “May raise ketamine levels”, “largely untested”, “appear uncommon” carried over |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Avoid/Caution/Monitor categories and contraindication thresholds match the ER |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | None appear in the QRS |
| 1.6 | The QRS does not introduce new attributions. | 🟢 |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No “you”/”your” found |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are glossed (e.g., “subcutaneous (under-the-skin)”, “Bile-flow (cholestatic) injury”) |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Lede notes benefit for adults without depression remains largely untested (l.433) |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Routes stated as “oral”, “sublingually”, “subcutaneous”, “intravenous” |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | |
| 3.2 | All “<span data-qrs-var="NAME">...</span>” from the [qrs_template] are present in the the QRS. |
🟢 | Diff against template shows all spans present |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Only variable content differs from template |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section used is empty |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol and Key Interactions labels match ER bold labels |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Each section condensed to key facts (mitigations, citations, magnitudes stripped); gate length driven by 9.2/9.5 completeness |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration is quoted and contains a colon |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | 26.9.29 |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | 2026-0930-0453 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Opus |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Opus 5.5 |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 09/30/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with “small, spaced oral doses of a prescription anesthetic … hoping to lift mood” |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 68 words |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 9 ER populations present |
| 8.3 | Individual [stop_items] are formatted as <li></li> |
🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing “all contraindications on esketamine labeling” stripped |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | e.g., “(moderate or severe)”, “(Child-Pugh class C, severe cirrhosis)”, NYHA class III–IV |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation used |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention --> |
N/A | Section is not empty |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 19 ER interactions present |
| 9.3 | Individual [caution_items] are formatted as <li></li> |
🟢 | |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mitigations and citations stripped |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation used |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no interaction that changes how the intervention is used --> |
N/A | Section is not empty |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Therapeutic Protocol l.371-376 |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Sublingual microdosing, per-kg oral dosing, time of day |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides more than three aspects |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Depression, suicidal thoughts, anxiety |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | High tier (depression) first, then Low-tier items |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides three aspects |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 9 ER table rows present |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 7 qualitative markers present |
Issues 30/09/2026 05:16
Pass rate 100.00%. No issues found.
Issues 30/09/2026 05:13
- 2.7 — Unexplained jargon in time cell: The Anxiety time-to-effect sub-text (line 511, time_3_sub) uses “subcutaneous” and “refractory” without plain-language explanation, although the ER glosses subcutaneous as “(under-the-skin)”.
Fixes 30/09/2026 05:13
- 2.7 — Unexplained jargon in time cell: Changed time_3_sub from “After subcutaneous doses … in refractory social and generalized anxiety” to “After subcutaneous (under-the-skin) doses … in treatment-resistant social and generalized anxiety”.
Issues 30/09/2026 05:11
- 2.7 — Unexplained vascular jargon in contraindications: Line 545 lists “Aneurysmal vascular disease” and “arteriovenous malformation” without the ER’s plain-language glosses (“ballooned artery walls”, “abnormal artery-vein tangle”), although adjacent terms such as intracerebral hemorrhage are glossed.
Fixes 30/09/2026 05:11
- 2.7 — Vascular jargon glosses added: In the Contraindications list, added the ER’s plain-language glosses “(ballooned artery walls)” after “Aneurysmal vascular disease” and “(abnormal artery-vein tangle)” after “arteriovenous malformation”.
Issues 30/09/2026 05:07
- 2.7 — Unexplained jargon in gates: “NMDA” appears unexpanded in the Magnesium and zinc interaction (line 575), and the contraindications drop the ER’s plain-language glosses for “intracerebral hemorrhage”, “unstable angina” and “Interstitial cystitis” (lines 545, 546, 549) while keeping “(heart attack)”.
Fixes 30/09/2026 05:07
- 2.7 — Restored plain-language glosses: Expanded “NMDA” to “NMDA (glutamate receptor)” in the Magnesium and zinc interaction, and restored the ER glosses “(bleeding within the brain)”, “(chest pain at rest)” and “(chronic bladder inflammation)” in the contraindications.
Issues 30/09/2026 05:04
- 2.7 — Unexplained medical jargon: Monitoring row “Resting heart rate” uses “Detect sympathetic stimulation” (line 634) and the Lamotrigine interaction uses “Attenuated perceptual and psychosis-like effects” (line 571); both use clinical jargon where plain-language terms are available.
Fixes 30/09/2026 05:04
- 2.7 — Unexplained medical jargon: Changed marker_2_why from “Detect sympathetic stimulation” to “Detect fight-or-flight stimulation” (ER’s own explanation of the sympathetic nervous system), and the Lamotrigine interaction from “Attenuated” to “Reduced perceptual and psychosis-like effects”.
Issues 30/09/2026 05:01
- 2.7 — Unglossed clinical jargon in contraindications: “Myocardial infarction” (line 546) and “Child-Pugh class C” (line 548) appear without the plain glosses “(heart attack)” and “(severe cirrhosis)” that the ER provides (ER lines 349, 351).
- 4.2 / 4.3 — Abbreviated interaction label: The bold label at line 562 drops “an older class of antidepressants” from the ER label “Stimulants and MAOIs (monoamine oxidase inhibitors, an older class of antidepressants; amphetamine, methylphenidate, phenelzine)” (ER line 320).
Fixes 30/09/2026 05:01
- 2.7 — Glossed contraindication jargon: Added “(heart attack)” after “Myocardial infarction” and changed “(Child-Pugh class C)” to “(Child-Pugh class C, severe cirrhosis)”, matching the ER glosses.
- 4.2 / 4.3 — Restored verbatim interaction label: Changed the label to “Stimulants and MAOIs (monoamine oxidase inhibitors, an older class of antidepressants; amphetamine, methylphenidate, phenelzine)” as in the ER.
Issues 30/09/2026 04:58
- 2.15 — Lay term for respiratory depression: The Opioids entry in caution_items (line 561) reads “Additive sedation and slowed breathing”, using the lay gloss instead of the formal term “respiratory depression” in ER line 315.
Fixes 30/09/2026 04:58
- 2.15 — Lay term for respiratory depression: Changed the Opioids entry in caution_items from “Additive sedation and slowed breathing” to “Additive sedation and respiratory depression”, which matches the ER’s formal term.
Issues 30/09/2026 04:55
- 2.7 — Unexpanded clinical acronyms: “NYHA class III–IV” in the contraindications (line 546) and “eGFR” in the monitoring marker name and target (lines 672, 675) appear without expansion, although other markers (ALT, GGT, PHQ-9, GAD-7) are expanded.
- 11.1 — Non-onset time-to-effect entry: time_2 “Depressive relapse / Over 13 weeks” (lines 494–500) is a trial observation window rather than a time to effect, while the ER’s explicit onset for anxiety (“reduced anxiety within an hour”) is omitted.
Fixes 30/09/2026 04:55
- 2.7 — Expanded clinical acronyms: Changed “heart failure (NYHA class III–IV)” to “heart failure (New York Heart Association class III–IV)” and “Creatinine and eGFR” to “Creatinine and eGFR (estimated glomerular filtration rate)”.
- 11.1 — Replaced non-onset time entry: Removed “Depressive relapse / Over 13 weeks”, moved “Suicidal thoughts / Within one day” to time_2, and added time_3 “Anxiety / Within an hour” (subcutaneous 0.25–1 mg/kg in refractory social and generalized anxiety) from the ER.